Browsing by Author "Rodríguez-Martínez, Carlos E."
Now showing 1 - 6 of 6
Results Per Page
Sort Options
- ItemChildren under 12 months could benefit from a therapeutic trial with bronchodilators if the clinical response is positive(2015) Rodríguez-Martínez, Carlos E.; Castro Rodríguez, José Antonio
- ItemDiscriminative properties of two predictive indices for asthma diagnosis in a sample of preschoolers with recurrent wheezing(2011) Rodríguez-Martínez, Carlos E.; Sossa-Briceño, Mónica P.; Castro Rodríguez, José Antonio
- ItemPredictors of hospitalization for asthma in children : Results of a 1-year prospective study(2014) Rodríguez-Martínez, Carlos E.; Sossa-Briceño, Mónica P.; Castro Rodríguez, José Antonio
- ItemThe asthma predictive index remains a useful tool to predict asthma in young children with recurrent wheeze in clinical practice(2011) Castro Rodríguez, José Antonio; Cifuentes, Lorena; Rodríguez-Martínez, Carlos E.
- ItemThe impact of viral bronchiolitis phenotyping : Is it time to consider phenotype-specific responses to individualize pharmacological management?(2019) Rodríguez-Martínez, Carlos E.; Castro Rodríguez, José Antonio; Nino, Gustavo.; Midullae, Fabio.
- ItemThe use of β2-adrenoreceptor agonists in viral bronchiolitis: scientific rationale beyond evidence-based guidelines(2020) Nino, Gustavo; Rodríguez-Martínez, Carlos E.; Castro Rodríguez, José AntonioDespite scientific evidence proving that inhaled β2-adrenergic receptor (β2-AR) agonists can reverse bronchoconstriction in all ages, current guidelines advocate against the use of β2-AR bronchodilators in infants with viral bronchiolitis because clinical trials have not demonstrated an overall clinical benefit. However, there are many different types of viral bronchiolitis, with variations occurring at an individual and viral level. To discard a potentially helpful treatment from all children regardless of their clinical features may be unwarranted. Unfortunately, the clinical criteria to identify the infants that may benefit from bronchodilators from those who do not are not clear. Thus, we summarised the current understanding of the individual factors that may help clinicians determine the highest probability of response to β2-AR bronchodilators during viral bronchiolitis, based on the individual immunobiology, viral pathogen, host factors and clinical presentation.